# Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

Study · id `cardio:ct-nct01512108` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01512108](<https://clinicaltrials.gov/study/NCT01512108>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01512108

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 363 participants.

## Technical summary

Registry record NCT01512108. Randomized; no masking; primary purpose treatment. Start 2012-01-10 (actual); primary completion 2013-04-26 (actual). Results posted on 2014-05-28.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 363 participants (enrolled count; ClinicalTrials.gov record NCT01512108, source copy `cardio:ctgov-nct01512108-2017-12-18`, retrieved 2026-10-26)
- Started: 2012-01-10 (actual) (ClinicalTrials.gov record NCT01512108, source copy `cardio:ctgov-nct01512108-2017-12-18`, retrieved 2026-10-26)
- Primary completion: 2013-04-26 (actual) (ClinicalTrials.gov record NCT01512108, source copy `cardio:ctgov-nct01512108-2017-12-18`, retrieved 2026-10-26)
- Completion: 2013-04-26 (actual) (ClinicalTrials.gov record NCT01512108, source copy `cardio:ctgov-nct01512108-2017-12-18`, retrieved 2026-10-26)
- Results first posted: 2014-05-28 (ClinicalTrials.gov record NCT01512108, source copy `cardio:ctgov-nct01512108-2017-12-18`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01512108, source copy `cardio:ctgov-nct01512108-2017-12-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01512108-2017-12-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): liraglutide
- Intervention (Drug): oral anti-diabetic drug
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial (`cardio:pubmed-26816604`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial (`cardio:pubmed-28984041`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f671fad228b45cb86fd3c8512256c30ce6582c8100a0af827e39477399d59069
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
